

TABLE OF CONTENTS

January 25, 2010

No. 2173

BUSINESS

- 1 Sales of Crestor in Japan to Exceed ¥100 Bil.
- PI for Ticagrelor Completed
- AZ, Astellas to Jointly Promote Symbicort with 2,700 MRs
- 3 Merck Serono to Increase Market Share for Gonalef, Saizen
- 4 Hisamitsu: Sales Up 5% Driven by Mohrus Series
- 4 Blopress Remains No. 1 for 6 Terms in a Row: Domestic Drugs Sales Ranking
- 5 26 Listed JPMA Member Companies' Combined Operating Profits Up 28.8% in 1st Half of FY2009
- 5 **BUSINESS NEWS IN BRIEF**
- Bayer to Transfer Shinbit to Hospira
- Ranbaxy Creates Japanese Subsidiary
- Mitsui & Co. Embarks on CRO Business in Asia
- 8 **Commentary**
- New Premium to Trouble Wholesalers Again

REGULATORY

- 9 Rate of New Premium for New Drug Development Will Be 5.10%
- 9 61% of Drug Companies Welcome New Pricing System: Questionnaire
- 10 Panel of Experts on Unapproved Drugs/Indications to Be Inaugurated
- 10 Companies Should Be Encouraged to Participate in New Growth Strategy: Mr Nagatsuma
- 11 Eisai Applies for Pediatric Indication for Flecainide Based on Data in Public Domain
- 11 Anti-Flu Agent Rapiacta Approved: Shionogi
- Med. Institutions Asked to Cooperate with All-Patient Survey on Rapiacta
- 12 Flu Vaccines from GSK, Novartis Receive First "Emergency Approval"
- 12 **REGULATORY NEWS IN BRIEF**
- New Subcommittee to Be Created for Regulatory Reform
- NCs to Take Over Part of Long-Term Debt
- *Koroshō* to Present Bill to Amend Preventive Vaccination Law
- No Serious Concern about Safety of New-Type Flu Vaccines Made in Japan

- Actemra Approved in the US: Chugai, Roche
- Pfizer Receives CRL for Lyrica Applied for GAD

GENERICS

- 14 Nichi-Iko to Enter the Market for Biosimilars: President Tamura
- Bio Laboratory to Be Constructed
- Record-High Sales, Profits
- 15 Latanoprost to See Generics from 23 Companies
- 15 **Seminar**
- Include Prevnar in Periodic Immunization Programs ASAP: Dr Wada

R&D

- 16 Eisai to Apply for Eribulin in Japan, the US and Europe in March
- 16 **R&D NEWS IN BRIEF**
- MK-8669 Enters PII in Japan: Banyu
- MBL, Osaka Univ. Isolate Fully-Human Flu Virus MAB
- Tasigna Shown to Be Superior to Glivec for CML: Novartis

MEDICAL DEVICES

- 17 Abbott's Everolimus-Eluting Stent XIENCE V Approved in Japan
- 18 **MEDICAL DEVICE NEWS IN BRIEF**
- Seikagaku Receives Not-Approvable Letter for Gel-200 from FDA

SELF-MEDICATION

- 18 **SELF-MEDICATION NEWS IN BRIEF**
- Kobayashi Aims at ¥4.5 Bil. with New Products in FY2010
- Gov't New Growth Strategy to Stimulate Market for OTC Drugs: Mr Hatori

TOPICS

- 18
- GLs for Ads on Illegal Drugs on Internet to Be Revised

MEDICAL FACILITIES & NURSING CARE

- 19 Informed Consent Not Obtained from Many Recipients of Albumin Products